Edmonds Duncan Registered Investment Advisors LLC Has $401,000 Position in Johnson & Johnson (JNJ)
Edmonds Duncan Registered Investment Advisors LLC continued to hold its stake in Johnson & Johnson (NYSE:JNJ) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,250 shares of the company’s stock at the end of the first quarter. Edmonds Duncan Registered Investment Advisors LLC’s holdings in Johnson & Johnson were worth $401,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of the company. Capital Guardian Trust Co. raised its stake in Johnson & Johnson by 5.4% in the fourth quarter. Capital Guardian Trust Co. now owns 260,514 shares of the company’s stock valued at $30,014,000 after buying an additional 13,276 shares in the last quarter. Pinnacle Financial Partners Inc. raised its stake in Johnson & Johnson by 37.9% in the fourth quarter. Pinnacle Financial Partners Inc. now owns 66,688 shares of the company’s stock valued at $7,684,000 after buying an additional 18,333 shares in the last quarter. Empire Life Investments Inc. bought a new stake in Johnson & Johnson during the fourth quarter valued at about $28,023,000. RB Capital Management LLC bought a new stake in Johnson & Johnson during the fourth quarter valued at about $638,000. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in Johnson & Johnson during the fourth quarter valued at about $277,294,000. Institutional investors own 65.98% of the company’s stock.
Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.81% during midday trading on Thursday, hitting $132.13. 1,320,524 shares of the stock traded hands. The firm’s 50-day moving average is $132.91 and its 200 day moving average is $127.75. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The company has a market capitalization of $354.64 billion, a price-to-earnings ratio of 22.36 and a beta of 0.78.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The firm had revenue of $18.84 billion during the quarter, compared to the consensus estimate of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The business’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.74 earnings per share. Equities analysts forecast that Johnson & Johnson will post $7.18 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be issued a dividend of $0.84 per share. The ex-dividend date is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.56%. Johnson & Johnson’s dividend payout ratio is presently 56.76%.
TRADEMARK VIOLATION NOTICE: “Edmonds Duncan Registered Investment Advisors LLC Has $401,000 Position in Johnson & Johnson (JNJ)” was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://www.watchlistnews.com/edmonds-duncan-registered-investment-advisors-llc-has-401000-position-in-johnson-johnson-jnj/1534314.html.
JNJ has been the topic of several research analyst reports. Vetr lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $128.90 price target on the stock. in a research report on Monday, May 8th. Jefferies Group LLC restated a “hold” rating and issued a $135.00 price target (down from $140.00) on shares of Johnson & Johnson in a research report on Sunday, May 14th. J P Morgan Chase & Co upgraded shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $123.64 to $140.00 in a research report on Monday, May 15th. UBS AG restated a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a research report on Monday, May 15th. Finally, Stifel Nicolaus restated a “hold” rating and issued a $128.00 price target (up from $124.00) on shares of Johnson & Johnson in a research report on Thursday, May 18th. Four analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and an average target price of $133.91.
In related news, VP Paulus Stoffels sold 102,692 shares of the company’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.